Liraglutide Regulates the Kidney and Liver in Diabetic Nephropathy Rats through the miR-34a/SIRT1 Pathway

Shan Xiao,1 Ye Yang,2 Yue-Tong Liu,3 and Jun Zhu1

1Department of Endocrinology, People’s Hospital of Shenzhen Baoan District, The Second School of Clinical Medicine, Southern Medical University, The Second Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China
2Department of No. 1 Cadres, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
3Department of Ultrasonic ECG, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Correspondence should be addressed to Jun Zhu; zhujun6677@163.com

Received 30 August 2020; Revised 25 February 2021; Accepted 23 March 2021; Published 7 April 2021

Academic Editor: Hiroshi Okamoto

Copyright © 2021 Shan Xiao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To explore the regulatory effects of liraglutide on the kidney and liver through the miR-34a/SIRT1 pathway with related factors in diabetic nephropathy (DN) rats. Methods. DN rats were randomly divided into two groups (n = 10) and were injected with liraglutide or normal saline twice a day. The 24-hour urine microalbumin content and biochemical index levels were measured. qRT-PCR was performed to detect the expression of miR-34a in the kidney and liver tissues. The levels of SIRT1, HIF-1a, Egr-1, and TGF-β1 in kidney and liver tissues were determined using qRT-PCR, western blot, and immunohistochemistry. Electron microscopy and HE staining were used to observe the ultrastructure and pathological changes. Results. Liraglutide treatment in DN rats decreased blood glucose, 24-hour urine microalbumin, TC, TG, LDL-C, UA, Cr, UREA, ALT, and AST levels and increased the level of HDL-C (P < 0.05). Compared with the control group, the miR-34a levels were significantly decreased in kidney and liver tissues followed by liraglutide treatment (P < 0.05). The levels of SIRT1 in the liraglutide group are significantly higher than those in the control group with the kidney and liver tissues (P < 0.05). Conversely, the contents of HIF-1a, Egr-1, and TGF-β1 were significantly lower in the liraglutide group than in the control group (P < 0.05). Electron microscopy showed that the kidney of the liraglutide-treated group exhibited minor broadening of the mesangial areas, fewer deposits, and a well-organized foot process. HE staining revealed that the kidney of the liraglutide-treated rats had a more regular morphology of the glomerulus and Bowman sac cavity and lighter tubular edema. Additionally, the liraglutide-treated DN rats had a clear hepatic structure, a lower degree of steatosis, and mild inflammatory cell infiltration. Conclusion. Liraglutide, through its effect on the miR-34a/SIRT1 pathway, may have a protective role in the kidney and liver of DN rats.

1. Introduction

Diabetes mellitus (DM) has now become a global health problem. Obesity or overweight, which is caused by lifestyle changes, is an important risk factor for type 2 DM (T2DM) [1, 2]. Diabetic nephropathy (DN) is a common microvascular complication of DM and is an important cause of end-stage renal disease. The pathogenesis of DN may be associated with abnormal renal hemodynamics, oxidative stress, and formation of glycosylation end products [3–6]. The primary pathological changes associated with DN include glomerular sclerosis, renal tubular atrophy, and renal interstitial fibers [7]. In addition to kidney disease, patients with DN may have abnormal liver metabolism [8]. Liraglutide, a glucagon-like peptide-1 (GLP-1) analog, has been proven to regulate lipid metabolism and is able to decrease blood glucose levels and body weight. Moreover, liraglutide improves urinary albumin levels, reduces kidney fibrosis, and delays DN progression [9–13]. Liraglutide also enhances the antioxidant capacity of hepatocytes by activating the NRF2 (nuclear factor erythroid 2-related factor 2) signaling pathway and reduces hepatocyte apoptosis that is mediated by glycolipid toxicity in diabetic and obese rats [14]. Recently, microRNAs (miRNAs) have become a research hotspot. miRNAs are endogenous, noncoding RNAs composed of 21-25 nucleotides. They suppress gene transcription or protein translation
by targeting the 3′-noncoding region (3′-UTR) of the target mRNA [15]. The importance of miRNAs in regulating critical signaling pathways and their consequent role in the pathogenesis of DN have been demonstrated in various studies [16–19]. In particular, miR-34a has been implicated in the development of fibrosis in various organs and early pathological changes in the kidney in DN [20]. In renal tubular epithelial cells, p53 activates the transforming growth factor-β1 (TGF-β1) and induces overexpression of miR-34a, which aggravates the degree of renal fibrosis following the unilateral ureteral obstruction (UUO) in mice [21]. Alterations in miR-34a expression levels have been shown to be closely related to liver fibrosis; activation of the miR-34a/SIRT1 pathway plays a critical role in fructose-induced liver fibrosis via the TGF-β1/Smads pathway in rats [22]. In glomerular mesangial cells treated with high glucose, overexpression of miR-34a inhibits

| Gene      | Forward primer       | Reverse primer       |
|-----------|----------------------|----------------------|
| SIRT1     | 5′-TGAAAGTAAGACCAGTGC-3′ | 5′-AATGTAAGATGAGGCAGAG-3′ |
| HIF-1α    | 5′-CTTCACCCAGCAAGCGA-3′ | 5′-TGCAAGGCAATAATAGTCC-3′ |
| Egr-1     | 5′-CTGGAGGAGATGATGC-3′ | 5′-GCTATTGCTGGCAGAT-3′ |
| TGF-β1    | 5′-GGCCATCCATCATGTAACCG-3′ | 5′-GGCGTACACACGCTTCTCTTCTTG-3′ |
| GAPDH     | 5′-CAAGTTCAACGGCCAG-3′ | 5′-CCAGTAAGCTCCAGCAT-3′ |
| miR-34a   | 5′-GGGTGCGGATGCTCCT-3′ | 5′-CTCGCTTCGGCAGACATATAC-3′ |
| U6        | 5′-CTCGCTTCGGCAGACATATAC-3′ | 5′-ACGTCCTAGAGATTTCGTC-3′ |

Note: Egr-1: early growth response-1; GADPH: glyceraldehyde 3-phosphate dehydrogenase; HIF-1α: hypoxia-inducible factor-1 alpha; TGF-β1: transforming growth factor-β.

**Figure 1:** Fasting blood glucose and 24-hour microalbumin content. Control: diabetic nephropathy group; DN+LG: diabetic nephropathy +liraglutide group; FBG: fasting blood glucose. *P < 0.05 vs. the control.

**Figure 2:** TC, TG, LDL-C, and HDL-C levels. Control: diabetic nephropathy group; DN+LG: diabetic nephropathy +liraglutide group; TC: total cholesterol; TG: triglyceride; LDL-C: low-density lipoprotein; HDL-C: high-density lipoprotein. *P < 0.05 vs. the control.
the expression of SIRT1 but increases the expression of the hypoxia-inducible factor-1α (HIF-1α) and early growth response-1 (Egr-1); this causes inflammation of the glomerular mesangial cells as well as an increase in the levels of profibrotic factors [23, 24]. Hypoxia has been shown to be an important inducing factor of inflammation and fibrosis in chronic liver disease; HIF-1α is a key transcription factor for liver fibrosis and is involved in the biliary ligation (BDL) and carbon tetrachloride- (CCL4-) induced liver fibrosis in rats [25–27]. HIF-1α was present in elevated levels in the liver of T2DM rats with fatty liver disease. Egr-1 is a proinflammatory nuclear transcription factor; Egr-1 knockout mice were shown to exhibit more severe liver fibrosis, which was induced by treatment with acetaminophen (APAP) [28]. Obesity and T2DM are often accompanied by insulinemia; long-term stimulation with high insulin induces the activation of Egr-1 in hepatocytes and reduces the regulatory effect of insulin. Conversely, inhibiting the expression of Egr-1 in the liver significantly reduces glucose production, thereby resulting in an improvement in glucose tolerance and insulin sensitivity [29].

Therefore, we established a rat model of DN using streptozotocin (STZ) and explored the effects of liraglutide on the expression of miR-34a and SIRT1 in the kidney and liver tissues. This study was aimed at investigating whether liraglutide has a role in protecting the kidney and liver of DN rats through the miR-34a/SIRT1 pathway; hence, this study could provide a theoretical basis for the use of liraglutide in the prevention and treatment of DN.

2. Procedures
2.1. Animals. SPF-grade male Sprague Dawley (SD) rats, weighing approximately 180–220 g, were provided by the Laboratory of Animal Center of Xinjiang Medical University.
This study was approved by the Institutional Animal Care and Use Committee (IACUC) of Xinjiang Medical University and performed in accordance with the rules and regulations of the Care and Use of Laboratory Animals.

2.2. Reagents. STZ was purchased from Sigma-Aldrich (USA); the TRIzol reagent was purchased from Ambion (USA); the cDNA reverse transcription kit and qRT-PCR kit were purchased from Qiagen (Germany); primers for SIRT1, HIF-1α, Egr-1, and TGF-β1 mRNAs in the kidney. Control: diabetic nephropathy group; DN+LRG: diabetic nephropathy+liraglutide group; Egr-1: early growth response-1; HIF-1α: hypoxia-inducible factor-1 alpha; TGF-β1: transforming growth factor-β1. *P < 0.05 vs. the control.

Figure 6: Expression levels of SIRT1, HIF-1α, Egr-1, and TGF-β1 mRNAs in the kidney. Control: diabetic nephropathy group; DN+LRG: diabetic nephropathy+liraglutide group; Egr-1: early growth response-1; HIF-1α: hypoxia-inducible factor-1 alpha; TGF-β1: transforming growth factor-β1. *P < 0.05 vs. the control.

Figure 7: Expression of SIRT1, HIF-1α, Egr-1, and TGF-β1 proteins in the kidney. Control: diabetic nephropathy group; DN+LRG: diabetic nephropathy+liraglutide group; Egr-1: early growth response-1; HIF-1α: hypoxia-inducible factor-1 alpha; TGF-β1: transforming growth factor-β1. *P < 0.05 vs. the control.
SIRT1, HIF-1α, Egr-1, and miR-34a were synthesized by Tianyihuiyuan Biotech (China); antibodies against TGF-β1, SIRT1, HIF-1α, and Egr-1 were purchased from Abcam (USA); liraglutide was purchased from Novo Nordisk (Denmark).

2.3. Instruments. The instruments used in our study included a portable blood glucose monitor and test paper (Accu-Chek, Germany), a PCR amplifier CFX96 (Bio-Rad, USA), an imaging system (Bio-Rad, USA), and an automatic chemiluminescence analyzer (Tianngeng Technology, China).

2.4. Model Establishment. Twenty SPF-grade male SD rats were fed with a high-fat and high-sugar diet for 8 weeks until their body weight increased to 400-450g. The high-fat and high-sugar diet was resumed once again after the rats were injected intraperitoneally with 1 dose of STZ (30 mg/kg). After 3 days, the tail vein blood was collected; blood glucose levels equal to or greater than 16.7 mmol/L were used as an indicator for the successful establishment of a diabetic model. A DN model was considered to be successfully established if the urine albumin excretion rate exceeded 20 mg/24 h and the model was considered to be successfully established if the glucose tolerance test indicated the levels of miR-34a were determined using a PCR reaction consisting of 40 cycles of denaturation at 95°C for 10 min, annealing at 60°C for 1 min, and extension at 95°C for 15 s. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the internal reference. The expression levels of miR-34a were determined by performing a PCR reaction consisting of 40 cycles of denaturation at 94°C for 15 min, annealing at 55°C for 30 s, and extension at 70°C for 30 s. The has-U6 was used as the internal reference. Each experiment was repeated at least 3 times. The relative levels of SIRT1, HIF-1α, Egr-1, TGF-β1, and miR-34a were determined using the 2<sup>-ΔΔCt</sup> (cycle threshold (CT)) formula.

2.5. Sample Collection. Following 12 weeks of treatment with liraglutide and normal saline, 24-hour urine samples were collected. Following an overnight fast, the rats were weighed and intraperitoneally injected with 3% pentobarbital sodium (40 mg/kg). Blood was collected from the abdominal aorta; a portion of each of the kidney and liver tissues was kept in RNAlater solution and stored at -80°C. Another portion was fixed with 4% paraformaldehyde and 2.5% glutaraldehyde for use in subsequent experiments.

2.6. 24-Hour Urinary Microalbumin. The 24-hour urine samples were collected and centrifuged at 2500 × g for 20 min. The supernatants were collected, and the absorbance was measured at a wavelength of 450 nm using a microplate analyzer. The microalbumin content of the urine was calculated according to the regression equation.

2.7. Serum Biochemical Indices. The blood samples were thawed at 4°C, and GLU, total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL-C), high-density lipoprotein (HDL-C), uric acid (UA), creatinine (Cr), urea (UREA), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) contents in the blood samples were determined using a BS-420 automatic biochemical analyzer.

2.8. Quantitative Real-Time PCR (qRT-PCR). Total RNAs from the kidney and liver tissues were extracted using the TRIzol reagent and reverse transcribed to cDNA. Primers for SIRT1, HIF-1α, Egr-1, and TGF-β1 are shown in Table 1. The PCR reaction included 40 cycles of denaturation at 95°C for 10 min, annealing at 60°C for 1 min, and extension at 95°C for 15 s. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the internal reference. The expression levels of miR-34a were determined by performing a PCR reaction consisting of 40 cycles of denaturation at 94°C for 15 min, annealing at 55°C for 30 s, and extension at 70°C for 30 s. The has-U6 was used as the internal reference. Each experiment was repeated at least 3 times. The relative levels of SIRT1, HIF-1α, Egr-1, TGF-β1, and miR-34a were determined using the 2<sup>-ΔΔCt</sup> (cycle threshold (CT)) formula.

2.9. Western Blot. The kidney and liver tissue samples were sonicated in the lysis buffer containing a phosphatase inhibitor and protease and were subsequently centrifuged at 14000 × g for 15 min at 4°C. The supernatants were collected, and the protein concentration was determined using a bicinchoninic acid (BCA) protein detection kit. Protein samples (20 μg/well) were separated on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel, transferred to a polyvinylidene fluoride (PVDF) membrane, and thereafter blocked in 5% bovine serum at room temperature for 2 h. The membranes were incubated with the primary antibodies against SIRT1 (1 : 1000), HIF-1α (1 : 1000), Egr-1 (80 kDa, 1 : 1000), TGF-β1 (1 : 1000), and GAPDH (1 : 5000) overnight at 4°C. After being washed with a Tris-buffered saline and Tween 20 (TBST) buffer three times, the membrane was incubated with horseradish peroxidase- (HRP-) labeled IgG (1 : 10000) at room temperature for 2 h. Following a three-time wash with TBST, the protein bands were detected using enhanced chemiluminescence (ECL) reagents to avoid light and color and take photos in gel electrophoresis apparatus. The gray value was measured by image processing software, and the relative expression level of the target protein was calculated by the gray value. GAPDH was used as an internal reference.

2.10. Immunohistochemistry. The kidney and liver tissue samples were fixed, embedded in paraffin, and dehydrated in graded alcohols. This was followed by quenching of endogenous peroxidases and antigen retrieval. Non-specific protein binding was inhibited with the serum. The experiment was performed using a primary antibody followed by an appropriate secondary antibody. Phosphate-
buffered saline (PBS) was used as the negative control, and brownish yellow particles were treated as positive signals.

2.11. Transmission Electron Microscopy. Kidney tissues were fixed with 2.5% glutaraldehyde for 2 h, rinsed overnight, and fixed with 1% osmic acid for 2 h. Thereafter, the tissues were dehydrated in gradient pyruvate acid and stained with lead and uranium. The ultrastructure was observed under a transmission electron microscope.

2.12. Hematoxylin/Eosin (HE) Staining. The kidney and liver tissues were fixed in 4% paraformaldehyde for 48 h, embedded in paraffin, and stained with hematoxylin/eosin (HE) for histopathological observation.
3. Results

3.1. Fasting Blood Glucose and 24-Hour Urine Microalbumin Changes. Following treatment with liraglutide, the blood glucose levels were significantly decreased in the DN rats \( (P < 0.05) \) (Figure 1(a)). Additionally, the 24-hour urine microalbumin content was also significantly reduced in the liraglutide-treated DN rats when compared to the control group \( (P < 0.05) \) (Figure 1(b)).

3.2. Changes in Biochemical Indices. Treatment with liraglutide resulted in a significant decrease in the serum levels of TC, TG, and LDL-C \( (P < 0.05) \) (Figures 2(a) and 2(b)); conversely, the level of HDL-C was increased \( (P < 0.05) \) in DN rats when compared with the control group (Figure 2(b)). Furthermore, the levels of blood UA, Cr, and UREA were significantly reduced in the liraglutide-treated DN rats than in the control group \( (P < 0.05) \) (Figure 3). AST and ALT levels were also significantly decreased (Figures 4(a) and 4(b)), and the AST/ALT ratio tended to be within the normal range (Figure 4(c)) following liraglutide treatment.

3.3. Liraglutide Inhibited the Expression of miR-34a in the Kidney of DN Rats. Through quantitative real-time PCR analyzing the miR-34a of extracted tissues, we found that compared to the control DN group, liraglutide treatment significantly decreased the expression of miR-34a in the renal tubules and glomeruli \( (P < 0.05) \) (Figure 13(b)–13(d), 14(b)–14(d), and 15).

3.4. Effect of Liraglutide on SIRT1 Downstream of miR-34a and Changes in Related Factors HIF-1a, Egr-1, and TGF-β1 in the Kidney of DN Rats. Compared to the control group, the mRNA and protein levels of SIRT1 were significantly increased (Figures 6(a), 7(a), and 8), whereas the mRNA and protein levels of HIF-1a, Egr-1, and TGF-β1 were found to be decreased \( (P < 0.05) \) (Figures 6(b)–6(d), 7(b)–7(d), and 8) in the kidney tissues of liraglutide-treated DN rats.

3.5. Ultrastructural and Pathological Changes in the Kidney of Liraglutide-Treated DN Rats. In the liraglutide-treated rats, we observed a slight widening of the mesangial area, an occasional appearance of deposits, mild edema of endothelial cells, and well-arranged foot processes in the kidney tissues (Figure 10). In the DN rats, electron microscopy revealed mesangial cell hyperplasia with lipid droplets, a widening of the mesangial area, low-density electron deposits, a shrunken basement membrane, a vascular cavity filled with a large number of red blood cells, and fusion foot processes (Figure 10).

3.6. Liraglutide Inhibited the Expression of miR-34a in the Liver of DN Rats. Through quantitative real-time PCR analyzing the miR-34a of extracted tissues, we found that compared to the control group, liraglutide treatment significantly decreased the expression of miR-34a in the liver tissues \( (P < 0.05) \) (Figure 12).

3.7. Effect of Liraglutide on SIRT1 Downstream of miR-34a and Changes in Related Factors HIF-1a, Egr-1, and TGF-β1 in the Liver of DN Rats. mRNA and protein levels of SIRT1 were significantly enhanced in liraglutide-treated rats compared to the control DN group (Figures 13(a), 14(a), and 15). In contrast, the expression levels of HIF-1a, Egr-1, and TGF-β1 mRNAs in the liver tissues were decreased \( (P < 0.05) \) (Figures 13(b)–13(d), 14(b)–14(d), and 15).

Immunohistochemical staining showed that the expression level of SIRT1 in the renal tubules and glomeruli was significantly increased following treatment with liraglutide (Figure 9(a)); conversely, the levels of HIF-1a, Egr-1, and TGF-β1 were decreased in the renal tubules and glomeruli of liraglutide-treated rats (Figures 9(b)–9(d)).

3.8. Pathological Changes in the Liver of Liraglutide-Treated DN Rats. In the liraglutide-treated DN rats, liver sinusoids were partially dilated (Figure 17). Conversely, disordered hepatic sinusoids with obvious dilation were detected in the liver of the control group (Figure 17).

4. Discussion

This study sought to investigate if liraglutide has a protective effect on the kidney and liver of DN rats that is mediated by
the miR-34a/SIRT1 pathway. To accomplish this, we established a DN rat model using STZ and explored the effects of liraglutide on the expression of miR-34a and SIRT1 in the kidney and liver tissues. As reported, GLP-1 is expressed by the glucagon gene; in islet α cells, glucagon is the main expression product of the glucagon gene; in intestinal mucosal L cells, prohormone converting enzyme (PC1) can cleave glucagon to its carboxyl-terminal peptide sequence, namely, GLP-1. GLP-1 can stimulate the proliferation and differentiation of islet β cells, inhibit the apoptosis of islet β cells, and

![Graph](image)

**Figure 13:** Expression of SIRT1, HIF-1α, Egr-1, and TGF-β1 mRNAs in the liver. Control: diabetic nephropathy group; DN+LRG: diabetic nephropathy+liraglutide group; Egr-1: early growth response-1; HIF-1α: hypoxia-inducible factor-1 alpha; TGF-β1: transforming growth factor-β1. *P < 0.05 vs. the control.

![Graph](image)

**Figure 14:** Expression of SIRT1, HIF-1α, Egr-1, and TGF-β1 proteins in the liver. Control: diabetic nephropathy group; DN+LRG: diabetic nephropathy+liraglutide group; Egr-1: early growth response-1; HIF-1α: hypoxia-inducible factor-1 alpha; TGF-β1: transforming growth factor-β1. *P < 0.05 vs. the control.
inhibit the release of glucagon; GLP-1 also has glucose concentration-dependent hypoglycemic effect [30, 31]. Liraglutide, a GLP-1 analog, is reported to delay gastric emptying, reduce food intake, and maintain stable blood glucose levels by promoting a glucose-dependent secretion of insulin and inhibiting the release of glucagon. Meanwhile, liraglutide also alleviates blood lipid levels in obese patients with T2DM and controls weight gain [32, 33], and compared with exenatide, liraglutide has higher safety and tolerance and more significant effect in improving beta cell function and insulin sensitivity [34]. Moreover, liraglutide could decrease the incidence of proteinuria in diabetic patients, reduce urine protein through anti-inflammatory and antioxidative stress activities, improve kidney function, and prevent the occurrence of DN and acute kidney injury [35]. Multiple studies have shown that miR-34a is closely associated with the occurrence of diabetes; miR-34a is significantly increased in the peripheral blood mononuclear cells in patients with T2DM and is correlated positively with LDL-C/HDL-C and negatively with TG/HDL-C [36]. TGF-β1 stimulation promotes the resynthesis of miR-34a in fibroblasts and increases miR-34a expression in microvessels; hence, TGF-β1 has a role in renal tubule-interstitial fibrosis [37]. Exogenous injection of miR-34a-containing microvesicles in mice promotes apoptosis of renal tubular cells, which in turn is closely related to renal fibrosis. In the presence of high glucose, downregulation of miR-34a inhibits the proliferation of mesangial cells; miR-34a regulates early mesangial proliferation and glomerular hypertrophy in DN by targeting the growth arrest-specific protein 1 (GAS1) [38]. Silent information regulator 1 (SIRT1), a nicotinamide adenine dinucleotide- (NAD⁺-) dependent deacetylase, plays an important role in the pathophysiology of kidney disease [39]. High glucose could induce HIF-1α expression, leading to the apoptosis of renal tubular epithelial cells; the polymorphism of HIF-1α Pro582Ser has differential effects on DN [40, 41]. High levels of Egr-1 result in an increase in the expression of profibrotic protein and influence DN development [42]. In glomerular mesangial cells cultured with high glucose, activation of the miR-34a/SIRT1 pathway upregulates the expression of HIF-1α and Egr-1, resulting in the overexpression of profibrotic factors, such as TGF-β1 and type IV collagen, in glomerular mesangial cells [23, 24].

In the present study, we detected changes in the biochemical indices and levels of miR-34a, SIRT1, HIF-1α, Egr-1, and TGF-β1 and explored whether liraglutide plays a protective role in DN rats through the regulation of the miR-34a/SIRT1 pathway. Our findings indicate a significant decrease in the levels of blood glucose, 24-hour urine microalbumin, TC, TG, LDL-C, UA, Cr, and UREA, while the HDL-C content was observed to be increased following liraglutide treatment. The data showed miR-34a expression to be significantly lower while SIRT1 levels were shown to be higher in the kidney of liraglutide-treated rats than control rats (P < 0.05); the mRNA and protein levels of HIF-1α, Egr-1, and TGF-β1 were significantly decreased following liraglutide treatment (P < 0.05). Immunohistochemical staining showed an obvious increase in SIRT1 levels while the levels of HIF-1α, Egr-1, and TGF-β1 were decreased in the renal tubules and glomeruli of DN rats (P < 0.05). Electron microscopy detected a slight widening of the mesangial area, occasional deposits, mild edema of endothelial cells, and well-arranged foot processes in the kidney tissues. In the DN rats, electron microscopy revealed mesangial cell hyperplasia with lipid droplets, a widening of the mesangial area, low-density electron deposits, a shrunken basement membrane, a large number of red blood cells filling the vascular cavity, and fusion foot processes. HE staining revealed that the kidney in liraglutide-treated rats had a more regular morphology of the glomerulus and Bowman sac cavity and lighter tubular edema. Conversely, the DN rats exhibited obvious pathological changes including irregular glomerular morphology, adhesion of the Bowman sac wall and visceral layer, increased number of cells, and renal tubular edema with partial necrosis. These findings suggest that liraglutide plays a protective role in the kidney of DN rats by decreasing the blood glucose/lipid levels and expression of miR-34, HIF-1α, Egr-1, and TGF-β1 while increasing the SIRT1 levels. Additionally, liraglutide treatment alleviates oxidative stress-induced injury in ZDF-induced DN rats [14]. During the process of epithelial-mesenchymal transition (EMT), inhibition of the miR-34a/SIRT1 pathway downregulates TGF-β1 expression in hepatocytes, thus playing an antifibrotic role [18]. HIF-1α is not only involved in kidney injury in DN but also closely related to inflammatory reactions and glucagon sensitivity in the liver [43]. Similarly, Egr-1 is not only involved in high glucose-induced mesangial cell injury but also associated with liver injury, which is mediated by various pathways [44, 45]. Therefore, our study further explored if liraglutide had a protective role in the liver by targeting the miR-34a/SIRT1 pathway. Our results showed that liraglutide treatment significantly decreased AST and ALT levels; moreover, the AST/ALT ratio also tended to be within the normal range. Data showed a significant decrease in the miR-34a and SIRT1 levels and suppressed HIF-1α, Egr-1, and TGF-β1 in the liver in DN rats (P < 0.05). Immunohistochemical staining showed that liraglutide treatment resulted in a significant increase in SIRT1 and a decrease in the protein levels of HIF-1α, Egr-1, and TGF-β1 in the hepatocytes of DN rats. From the staining of the liver with HE, a partial dilation of the liver sinusoids was observed in the liraglutide-treated DN rats. Conversely, a disordered hepatic sinusoid, which presented
with obvious dilation, was detected in the control group, which had not received the liraglutide treatment. These findings suggest that liraglutide plays a protective role in the liver of DN rats by decreasing AST and ALT levels and miR-34a expression while increasing SIRT1 levels and inhibiting HIF-1α, Egr-1, and TGF-β1. Notably, the precise mechanism is unclear and requires further study.

5. Conclusion

In short, liraglutide plays a protective role in the kidney and liver of DN rats by decreasing miR-34a expression, increasing SIRT1 levels, and inhibiting HIF-1α, Egr-1, and TGF-β1. These findings provide a theoretical basis for the use of liraglutide in the prevention and treatment of DN.

Data Availability

The data analyzed during the study are not publicly available. Rigorous analysis of the data in order to ensure the objective authenticity of the results.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

The authors are grateful to all study participants. This work was supported by the State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia Fund (grant no. SKL-HIDCA-2018-12) and the Natural Science Foundation of China (grant no. 81660155).

References

[1] E. T. Callcott, A. B. Santhakumar, J. Luo, and C. L. Blanchard, “Therapeutic potential of rice-derived polyphenols on obesity-related oxidative stress and inflammation,” Journal of Applied Biomedicine, vol. 16, no. 4, pp. 255–262, 2018.

[2] M. J. Yahya, P. B. Ismail, N. B. Nordin et al., “CNDP1, NOS3, and MnSOD Polymorphisms as Risk Factors for Diabetic Nephropathy among Type 2 Diabetic Patients in Malaysia,” Journal of Nutrition and Metabolism, vol. 2019, Article ID 8736215, 13 pages, 2019.
[3] R. Bassi, A. Vergani, F. D’Addio et al., “Positive effects of a novel non-peptidyl low molecular weight radical scavenger in renal ischemia/reperfusion: a preliminary report,” SpringerPlus, vol. 3, no. 1, p. 158, 2014.

[4] P. Maffi, F. Bertuzzi, F. de Tedde et al., “Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy,” Diabetes Care, vol. 30, no. 5, pp. 1150–1155, 2007.

[5] A. Doria, M. A. Niewczas, and P. Fiorina, “Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy?,” Seminars in Nephrology, vol. 32, no. 5, pp. 437–444, 2012.

[6] C. C. Yu, A. Foroni, A. Weins et al., “Abatacept in B7-1-positive proteinuric kidney disease,” The New England Journal of Medicine, vol. 369, no. 25, pp. 2416–2423, 2013.

[7] A. Ali, “Diabetic nephropathy &dash; complications and treatment,” International Journal of Nephrology and Renovascular Disease, vol. 7, pp. 361–381, 2014.

[8] L. Porepa, J. G. Ray, P. Sanchez-Romeu, and G. L. Booth, “ Newly diagnosed diabetes mellitus as a risk factor for serious liver disease,” CMAJ, vol. 182, no. 11, pp. E526–E531, 2010.

[9] F. Sun, S. Chai, L. Li et al., “Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis,” BMJ, vol. 2015, article 157201, pp. 1–9, 2015.

[10] B. J. von Scholten, F. Persson, S. Rosenlund et al., “ The effect of liraglutide on renal function: a randomized clinical trial,” Diabetes, Obesity & Metabolism, vol. 19, no. 2, pp. 239–247, 2017.

[11] S. P. Marso, G. H. Daniels, K. Brown-Forandsen et al., “Liraglutide and cardiovascular outcomes in type 2 diabetes,” The New England Journal of Medicine, vol. 375, no. 4, pp. 311–322, 2016.

[12] L. Li and S. Lu, “Effect of liraglutide on renal pathological changes in diabetic rats,” China Pharmaceutical, vol. 23, no. 14, pp. 20–22, 2014.

[13] E. H. Zobel, B. J. von Scholten, B. Goldman, F. Persson, T. W. Hansen, and P. Rossing, “ Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: individual effects of treatment.” Diabetes, Obesity & Metabolism, vol. 21, no. 5, pp. 1261–1265, 2019.

[14] J. Guo, C. Li, C. Yang et al., “Liraglutide reduces hepatic glucolipotoxicity induced liver cell apoptosis through NRF2 signaling in Zucker diabetic fatty rats,” Molecular Medicine Reports, vol. 17, pp. 8316–8324, 2018.

[15] K. Bhatt, Q. S. Mi, and Z. Dong, “MicroRNAs in kidneys: biogenesis, regulation, and pathophysiological roles,” American Journal of Physiology-Renal Physiology, vol. 300, no. 3, pp. F602–F610, 2011.

[16] T. Sun, Y. Liu, L. Liu, and F. Ma, “MicroRNA-544 attenuates diabetic renal injury via suppressing glomerulosclerosis and inflammation by targeting FASN,” Gene, vol. 723, article 143986, 2020.

[17] Y. Feng, M. Y. Jin, D. W. Liu, and L. Wei, “Correction: Proteasome subunit-α type-6 protein is post-transcriptionally repressed by the microRNA-4490 in diabetic nephropathy,” Biosciences Reports, vol. 39, no. 1, p. 39, 2019.

[18] G. Wang, Y. Yan, N. Xu, Y. Hui, and D. Yin, “Upregulation of microRNA-424 relieved diabetic nephropathy by targeting Rictor through mTOR complex2/protein kinase B signaling,” Journal of Cellular Physiology, vol. 234, no. 7, pp. 11646–11653, 2019.

[19] F. X. Zhu, H. L. Wu, J. X. Chen, B. Han, and Y. F. Guo, “Dysregulation of microRNA-181b and TIMP3 is functionally involved in the pathogenesis of diabetic nephropathy,” Journal of Cellular Physiology, vol. 234, no. 10, pp. 18963–18969, 2019.

[20] M. K. dos Santos Nunes, A. S. Silva, I. Wanderley de Queiroga Evangelista et al., “Analysis of the DNA methylation profiles of miR-9-3, miR-34a, and miR-137 promoters in patients with diabetic retinopathy and nephropathy,” Journal of Diabetes and its Complications, vol. 32, no. 6, pp. 593–601, 2018.

[21] Y. Liu, X. Bi, J. Xiong et al., “MicroRNA-34a promotes renal fibrosis by downregulation of klotho in tubular epithelial cells,” Molecular Therapy, vol. 27, no. 5, pp. 1051–1065, 2019.

[22] L. Song, T. Y. Chen, X. J. Zhao et al., “Peroxisome proliferator-activated receptor agonists on weight loss in patients with type 2 diabetes: what is up, what is down?, The New England Journal of Medicine, vol. 375, no. 25, pp. 2416–2423, 2018.
cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study,” *Diabetes, Obesity & Metabolism*, vol. 21, no. 1, pp. 84–94, 2019.

[34] K. Z. Alshali and A. M. Karawagh, "A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes," *Saudi Medical Journal*, vol. 37, no. 8, pp. 834–842, 2016.

[35] J. F. Mann, D. D. Ørsted, K. Brown-Frandsen et al., "Liraglutide and renal outcomes in type 2 diabetes," *The New England Journal of Medicine*, vol. 377, no. 9, pp. 839–848, 2017.

[36] Y. Shen, H. Xu, X. Pan et al., “miR-34a and miR-125b are upregulated in peripheral blood mononuclear cells from patients with type 2 diabetes mellitus," *Experimental and Therapeutic Medicine*, vol. 14, no. 6, article 10.3892/etm.2017.5254, pp. 5589–5596, 2017.

[37] Y. Zhou, M. Xiong, J. Niu et al., "Secreted fibroblast-derived miR-34a induces tubular cell apoptosis in fibrotic kidney," *Journal of Cell Science*, vol. 127, no. 20, pp. 4494–4506, 2014.

[38] L. Zhang, S. He, S. Guo et al., "Down-regulation of miR-34a alleviates mesangial proliferation in vitro and glomerular hypertrophy in early diabetic nephropathy mice by targeting GAS1," *Journal of Diabetes and its Complications*, vol. 28, no. 3, pp. 259–264, 2014.

[39] D. H. Kim, Y. J. Jung, J. E. Lee et al., “SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53," *American Journal of Physiology. Renal Physiology*, vol. 301, no. 2, pp. F427–F435, 2011.

[40] X. Zhang, T. Guan, B. Yang, Z. Chi, Q. Wan, and H. F. Gu, "Protective effect of berberine on high glucose and hypoxia-induced apoptosis via the modulation of HIF-1α in renal tubular epithelial cells," *American Journal of Translational Research*, vol. 11, no. 2, pp. 669–682, 2019.

[41] H. F. Gu, X. Zheng, N. Abu Seman et al., "Impact of the hypoxia-inducible factor-1 (HIF1A) Pro582Ser polymorphism on diabetes nephropathy," *Diabetes Care*, vol. 36, no. 2, pp. 415–421, 2013.

[42] F. Zha, X. Qu, B. Tang et al., "Ginsenoside Rg5 attenuates hepatic glucagon response via suppression of succinate-associated HIF-1α induction in HFD-fed mice," *Diabetologia*, vol. 60, no. 6, article 4238, pp. 1084–1093, 2017.

[43] S. Lai, J. Yuan, D. Zhao et al., "Regulation of mice liver regeneration by early growth response-1 through the GGPPS/RAS/MAPK pathway," *The International Journal of Biochemistry & Cell Biology*, vol. 64, pp. 147–154, 2015.

[44] K. Man, T. K. Lee, T. B. Liang et al., “FK 409 ameliorates small-for-size liver graft injury by attenuation of portal hypertension and down-regulation of Egr-1 pathway," *Annals of Surgery*, vol. 240, no. 1, pp. 159–168, 2004.